B Cell Unit, Immunology Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Clin Exp Immunol. 2022 Sep 29;209(3):259-261. doi: 10.1093/cei/uxac080.
During the last 2 years and a half, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide, causing about 6 million deaths. Clinical manifestations are highly variable, ranging from entirely asymptomatic infection to multiorgan failure and death. The outcome in immunocompromised patients is still a matter of debate, and so are the optimal strategies to prevent or treat the infection in these high-risk populations.
在过去的两年半中，严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）在全球范围内传播，导致约 600 万人死亡。临床表现差异很大，从完全无症状感染到多器官衰竭和死亡。免疫功能低下患者的预后仍存在争议，对于这些高危人群，预防或治疗感染的最佳策略也是如此。
